Evidence map›Paper›PMID 41142664›Full record

ArticleO&G open2025

Minimizing Travel Burden of Gynecologic Cancer Surveillance Through a Unique Multidisciplinary Telehealth Program.

Avni Shridhar, Suzanne Viator, Tara Castellano, Holly Provost, Navya Nair, Elizabeth Neupert, Amma Agyemang, Amelia Jernigan

Abstract read
In one paragraph

Article in O&G open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Avni ShridharSection of Gynecologic Oncology, Department of Obstetrics and Gynecology, School of Medicine, Louisiana State University Health Sciences Center New Orleans, and the Department of Gynecologic Oncology, University Medical Center New Orleans LCMC Health, New Orleans, and the Section of Gynecologic Services, Ochsner University Hospital & Clinics, Lafayette, Louisiana; and the Section of Gynecological Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Miller School of Medicine, University of Miami, Miami, Florida.
Suzanne ViatorSection of Gynecologic Oncology, Department of Obstetrics and Gynecology, School of Medicine, Louisiana State University Health Sciences Center New Orleans, and the Department of Gynecologic Oncology, University Medical Center New Orleans LCMC Health, New Orleans, and the Section of Gynecologic Services, Ochsner University Hospital & Clinics, Lafayette, Louisiana; and the Section of Gynecological Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Miller School of Medicine, University of Miami, Miami, Florida.
Tara CastellanoSection of Gynecologic Oncology, Department of Obstetrics and Gynecology, School of Medicine, Louisiana State University Health Sciences Center New Orleans, and the Department of Gynecologic Oncology, University Medical Center New Orleans LCMC Health, New Orleans, and the Section of Gynecologic Services, Ochsner University Hospital & Clinics, Lafayette, Louisiana; and the Section of Gynecological Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Miller School of Medicine, University of Miami, Miami, Florida.
Holly ProvostSection of Gynecologic Oncology, Department of Obstetrics and Gynecology, School of Medicine, Louisiana State University Health Sciences Center New Orleans, and the Department of Gynecologic Oncology, University Medical Center New Orleans LCMC Health, New Orleans, and the Section of Gynecologic Services, Ochsner University Hospital & Clinics, Lafayette, Louisiana; and the Section of Gynecological Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Miller School of Medicine, University of Miami, Miami, Florida.
Navya NairSection of Gynecologic Oncology, Department of Obstetrics and Gynecology, School of Medicine, Louisiana State University Health Sciences Center New Orleans, and the Department of Gynecologic Oncology, University Medical Center New Orleans LCMC Health, New Orleans, and the Section of Gynecologic Services, Ochsner University Hospital & Clinics, Lafayette, Louisiana; and the Section of Gynecological Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Miller School of Medicine, University of Miami, Miami, Florida.
Elizabeth NeupertSection of Gynecologic Oncology, Department of Obstetrics and Gynecology, School of Medicine, Louisiana State University Health Sciences Center New Orleans, and the Department of Gynecologic Oncology, University Medical Center New Orleans LCMC Health, New Orleans, and the Section of Gynecologic Services, Ochsner University Hospital & Clinics, Lafayette, Louisiana; and the Section of Gynecological Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Miller School of Medicine, University of Miami, Miami, Florida.
Amma AgyemangSection of Gynecologic Oncology, Department of Obstetrics and Gynecology, School of Medicine, Louisiana State University Health Sciences Center New Orleans, and the Department of Gynecologic Oncology, University Medical Center New Orleans LCMC Health, New Orleans, and the Section of Gynecologic Services, Ochsner University Hospital & Clinics, Lafayette, Louisiana; and the Section of Gynecological Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Miller School of Medicine, University of Miami, Miami, Florida.
Amelia JerniganSection of Gynecologic Oncology, Department of Obstetrics and Gynecology, School of Medicine, Louisiana State University Health Sciences Center New Orleans, and the Department of Gynecologic Oncology, University Medical Center New Orleans LCMC Health, New Orleans, and the Section of Gynecologic Services, Ochsner University Hospital & Clinics, Lafayette, Louisiana; and the Section of Gynecological Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Miller School of Medicine, University of Miami, Miami, Florida.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveSTEEL MAGNOLIAS (shared telehealth for multidisciplinary gynecologic cancer survivorship) is a novel gynecologic cancer surveillance care-delivery program in which rural patients see a close-by gynecologist in person with simultaneous virtual gynecologic oncology consultation. This study assesses feasibility of STEEL MAGNOLIAS by examining travel burden reduction, cancer outcomes, visit activities, guideline adherence, and patient satisfaction.

methodsWe retrospectively reviewed charts of patients with gynecologic cancer in remission under the STEEL MAGNOLIAS program in rural south Louisiana (March 2020-September 2023). Travel metrics, patient satisfaction, cancer outcomes, survival status, reasons for visit, and adherence to follow-up as per National Comprehensive Cancer Network (NCCN) guidelines were recorded. A small subset of patients prospectively completed questionnaires, such as the COST-FACIT (Comprehensive Score for Financial Toxicity-Functional Assessment of Chronic Illness Therapy) for financial toxicity and the PSQ-18 (Patient Satisfaction Questionnaire Short Form), and responded to questions about existing barriers to care. Descriptive statistics and Wilcoxon rank sum tests for continuous data were used. We assessed feasibility by assessing continued patient compliance without erosion of satisfaction.

resultsSixty-three patients attended 178 STEEL MAGNOLIAS appointments, and most of the patients had a history of endometrial cancer. The majority, 82.5%, were alive with no evidence of disease. Our patients traveled a median of 16.9 miles for STEEL MAGNOLIAS, compared with 137 miles for in-person visits. We identified prevalent transportation and technology barriers to in-person and conventional virtual visits. Patients demonstrated high satisfaction with appointments. Genitourinary and cancer therapy symptoms and reviews of laboratory test results and imaging often were discussed. Laboratory tests, imaging, and referrals were ordered and completed at high rates, with 76.9% of appointments adhering to NCCN follow-up guidelines.

conclusionThe STEEL MAGNOLIAS program is a feasible, innovative hybrid telehealth model for rural gynecologic cancer surveillance that reduces travel burdens and ensures high guideline adherence and patient satisfaction. This scalable model has potential to improve outcomes and compliance, meeting patients where they are and transforming cancer survivorship.

Identifiers

PMID41142664
PMCPMC12551734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.